Assistant Professor of Medicine, Mayo Clinic College of Medicine
Hematology
Dr. Craig B. Reeder, MD
|
|
Give Review
Craig Reeder practices Hematology. He received 2 awards: "Top Doctors:Arizona State" and "Super Doctor". Craig Reeder is also published. He has 47 publications published. The lastest publication: "Long-term results of laparoscopic splenectomy for immune thrombocytopenic purpura.' Craig Reeder accepts Medicare payments and is registered with Medicare.gov.
Publications
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed Myeloma.
- Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple Myeloma.
- Weekly dosing of the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple Myeloma: results from a phase 1 study.
- Outcomes of hematopoietic cell transplantation for diffuse large B cell Lymphoma transformed from follicular Lymphoma.
- Phase 2 trial of intravenously administered plerixafor for stem Cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin Lymphoma who received prior stem cell transplantation.
- Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults using Fludarabine, BCNU, Melphalan, and Antithymocyte Globulin (FBM-A): Outcomes depen...
- Waldenström macroglobulinaemia: the key questions.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- Histologic remission of cardiac amyloidosis: a case report.
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multi...
- The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin Lymphoma of distinct histological origin.
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple Myeloma: Results from a phase 2 trial.
- Novel therapeutic agents for B-cell Lymphoma: developing rational combinations.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin Lymphoma.
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple Myeloma.
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple Myeloma: a comparative analysis of 411 patients.
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Treatment of newly diagnosed multiple Myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
- Mayo clinic consensus statement for the use of bisphosphonates in multiple Myeloma.
- Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple Myeloma.
- Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin Lymphoma: a phase II trial in the North Central Cancer Treatment Group.
- Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological Disorders and to assess response to treatment with Lenalidomide.
- Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
- A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with Chronic lym...
- Lenalidomide in the Myelodysplastic syndrome with chromosome 5q deletion.
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory Disease.
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple Myeloma: high response rates in a phase II clinical trial.
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin''s Lymphoma.
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive Lymphoma.
- Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom Macroglobulinemia.
- A practical guide to defining high-risk Myeloma for clinical trials, patient counseling and choice of therapy.
- Long-term results of laparoscopic splenectomy for Immune thrombocytopenic purpura.
- The evolution of Hodgkin's Disease and necrobiotic xanthogranuloma syndrome.
- Compromised stem Cell mobilization following induction therapy with lenalidomide in myeloma.
- Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell Lymphomas: phase I study.
- CD5+ persistent polyclonal B-cell Lymphocytosis in a male.
- Hepatic B-cell non-Hodgkin''s Lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection.
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell Lymphoma.
- Eosinophil-mediated bile duct stricture. A case studied by immunohistochemistry.
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem Cell transpla...
Schools
Southern Illinois University School Of Medicine
Mayo Grad School
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Burkitt's Lymphoma
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Top Doctors:Arizona State
- Super Doctor
Education
-
Mayo School of Graduate Medical Education
Hospital
-
Mayo Clinic - Rochester, Minnesota -
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER | 1134102536 | |
| NPPES Provider LastName | REEDER | |
| NPPES Provider FirstName | CRAIG | |
| NPPES Provider ZIPCode | 852595404 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hematology | |
| Total Claim Count | 751.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134102536 |
| Last Name Of The Provider | REEDER |
| First Name Of The Provider | CRAIG |
| View All |
Similar Doctors
|
|
Dr. Rafael Fonseca, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Mahesh Seetharam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruben A. Mesa, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Pierre Noel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raoul Tibes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa O. Sproat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Surabhi Amar, MD |
|
|
Dr. Tom R. Fitch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Helen J. Ross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph R. Mikhael, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ryan Robetorye, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Joanne L. Schlesinger, NP |